A pharmaceutical composition for the treatment of acute myeloid leukemia with a FLT3 mutation

摘要

There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4-antagonistic peptide.